Form 4: Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Stock Transactions
SEC Form 4
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.
Summary
- Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On February 12, 2025, Lippoldt acquired 38,252 stock options and 7,169 restricted stock units.
- On February 13, 2025, Lippoldt exercised options to acquire 2,083 and 2,017 shares of common stock.
- Also on February 13, 2025, Lippoldt sold 1,098 shares at a weighted average price of $116.76 and 1,086 shares at a weighted average price of $116.7495.
- These sales were executed under Rule 10b5-1 trading plans adopted on March 15, 2023, and June 14, 2024.
- Following these transactions, Lippoldt beneficially owns 43,405 shares of common stock, 38,252 stock options, and 6,053 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the pharmaceutical industry, with companies like Amgen, Gilead Sciences, and Biogen also subject to similar reporting requirements.
- The use of 10b5-1 trading plans is a standard method for insiders to sell shares while avoiding accusations of trading on non-public information, aligning with practices seen across various publicly traded companies.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company.
- The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023/03/15 | Date of adoption of Rule 10b5-1 trading plan. |
| 2023/02/13 | Date of RSU grant. |
| 2024/02/13 | Date of RSU grant. |
| 2024/06/14 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025/02/12 | Acquisition of stock options and restricted stock units. |
| 2025/02/13 | Exercise of stock options and sale of common stock. |
| 2025/03/12 | Vesting start date for stock options. |
| 2026/02/12 | First vesting date for 1/4 of the Restricted Stock Units. |
| 2026/02/13 | Vesting date for 2,083 shares. |
| 2027/02/12 | Second vesting date for 1/4 of the Restricted Stock Units. |
| 2027/02/13 | Vesting date for 2,083 shares and 2,017 shares. |
| 2028/02/12 | Third vesting date for 1/4 of the Restricted Stock Units. |
| 2028/02/13 | Vesting date for 2,018 shares. |
| 2029/02/12 | Fourth vesting date for 1/4 of the Restricted Stock Units. |
| 2035/02/12 | Expiration date of stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Rule 10b5-1, Neurocrine Biosciences, NBIX, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.